Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2011

01.10.2011 | Review Article

Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon

verfasst von: Eiji Kusano

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

In Japan, the number of chronic kidney disease (CKD) patients is thought to be 13,300,000, next in size after those with hypertension and diabetes. Although the number of patients with CKD seems large, it does not mean that all these patients require special treatment. Among them, nephrologists should pay special attention to patients with glomerular filtration rate below 50 mL/min/1.73 m2 and progressive deterioration of renal function. Treatment of these CKD patients by a limited number of specialists is simply impossible; hence, it is essential to request treatment from physicians who are involved in general internal medicine and primary care. It is well known that not only does CKD cause end-stage renal failure, it also causes the onset of cardiovascular diseases (CVD) such as cardiac infarction and cerebral stroke; however, the question is how much significance does CKD have as a risk factor for CVD. It is understandable that hypertension and CVD are often complications of CKD; however, in addition to what is conventionally mentioned, there are three or four mechanisms that we would like to emphasize, and discuss herein. Among them, we would like to stress the role of klotho genes with special reference to the generation of CVD in CKD patients. When patients develop CKD, it is therefore necessary to remove as far as possible any factors that could represent a risk for CVD. Moreover, by taking appropriate measures against clinical conditions that often complicate CKD, such as hypertension, renal anemia, hyperuricemia, and hyperlipidaemia, the development of CVD can be prevented.
Literatur
1.
Zurück zum Zitat Japanese Society of Nephrology, editors. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Tokyo Igakusha. 2009. Japanese Society of Nephrology, editors. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Tokyo Igakusha. 2009.
2.
Zurück zum Zitat Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:631–2.CrossRef Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:631–2.CrossRef
3.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
4.
Zurück zum Zitat Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.CrossRefPubMed Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.CrossRefPubMed
5.
Zurück zum Zitat Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159–66.CrossRefPubMed Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159–66.CrossRefPubMed
6.
Zurück zum Zitat Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24(7):1246–52.CrossRefPubMed Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24(7):1246–52.CrossRefPubMed
7.
Zurück zum Zitat Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921–6 (Epub 2003 Oct 2).CrossRefPubMed Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921–6 (Epub 2003 Oct 2).CrossRefPubMed
8.
Zurück zum Zitat Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Kusano E, et al. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin. 2003;19(7):627–33.CrossRefPubMed Eizawa T, Murakami Y, Matsui K, Takahashi M, Muroi K, Kusano E, et al. Circulating endothelial progenitor cells are reduced in hemodialysis patients. Curr Med Res Opin. 2003;19(7):627–33.CrossRefPubMed
9.
Zurück zum Zitat Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Kusano E, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69(10):1780–5.CrossRefPubMed Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Kusano E, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69(10):1780–5.CrossRefPubMed
10.
Zurück zum Zitat Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res. 2004;27(2):121–6.CrossRefPubMed Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res. 2004;27(2):121–6.CrossRefPubMed
11.
Zurück zum Zitat Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol. 2007;27(1):30–5.CrossRefPubMed Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol. 2007;27(1):30–5.CrossRefPubMed
12.
Zurück zum Zitat Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant. 2008;23(6):1892–901.CrossRefPubMed Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant. 2008;23(6):1892–901.CrossRefPubMed
13.
Zurück zum Zitat Fujii H. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24(7):2089–95.CrossRefPubMed Fujii H. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24(7):2089–95.CrossRefPubMed
14.
Zurück zum Zitat Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–8.CrossRefPubMedPubMedCentral Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–8.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Masuda T, Murata M, Honma S, Iwazu Y, Kusano E, Asano Y et al. Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant. 2011. Masuda T, Murata M, Honma S, Iwazu Y, Kusano E, Asano Y et al. Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant. 2011.
16.
Zurück zum Zitat Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19–25.CrossRefPubMed Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163:19–25.CrossRefPubMed
17.
Zurück zum Zitat Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Nabeshima YI, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.CrossRefPubMed Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Nabeshima YI, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.CrossRefPubMed
19.
Zurück zum Zitat Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004;29(4):91–9.CrossRefPubMed Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004;29(4):91–9.CrossRefPubMed
20.
Zurück zum Zitat Torres PU, Prié D, Molina-Blétry V, Beck L, Silve C, Friedlander G. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int. 2007;71(8):730–7.CrossRefPubMed Torres PU, Prié D, Molina-Blétry V, Beck L, Silve C, Friedlander G. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int. 2007;71(8):730–7.CrossRefPubMed
21.
Zurück zum Zitat Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA. 2007;104(7):2331–6 (Epub 2007 Feb 7).CrossRefPubMedPubMedCentral Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA. 2007;104(7):2331–6 (Epub 2007 Feb 7).CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA. 2008;105(28):9805–10.CrossRefPubMedPubMedCentral Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA. 2008;105(28):9805–10.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Cha SK, Hu MC, Kurosu H, Kuro-o M, Moe O, Huang CL. Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol Pharmacol. 2009;76(1):38–46.CrossRefPubMedPubMedCentral Cha SK, Hu MC, Kurosu H, Kuro-o M, Moe O, Huang CL. Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol Pharmacol. 2009;76(1):38–46.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Kuro-o M, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829–33.CrossRefPubMedPubMedCentral Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Kuro-o M, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309(5742):1829–33.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317(5839):803–6.CrossRefPubMed Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317(5839):803–6.CrossRefPubMed
26.
Zurück zum Zitat Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, Takahashi M, Boothman DA, Kuro-O M. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286(10):8655–65.CrossRefPubMedPubMedCentral Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, Takahashi M, Boothman DA, Kuro-O M. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286(10):8655–65.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Bose S, French S, Evans FJ, Joubert F, Balaban RS. Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem. 2003;278(40):39155–65.CrossRefPubMed Bose S, French S, Evans FJ, Joubert F, Balaban RS. Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem. 2003;278(40):39155–65.CrossRefPubMed
28.
Zurück zum Zitat Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, et al. Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116–24.CrossRefPubMed Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, et al. Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116–24.CrossRefPubMed
29.
30.
Zurück zum Zitat Tonelli M, Sacks F, Pfeffer M, et al. Relation between serumphosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627–33.CrossRefPubMed Tonelli M, Sacks F, Pfeffer M, et al. Relation between serumphosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627–33.CrossRefPubMed
31.
Zurück zum Zitat Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.PubMed Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–8.PubMed
32.
Zurück zum Zitat Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161(22):2661–7.CrossRefPubMed Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161(22):2661–7.CrossRefPubMed
33.
Zurück zum Zitat Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin–angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543–9.CrossRefPubMed Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin–angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543–9.CrossRefPubMed
34.
Zurück zum Zitat Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Matsuoka H et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res. 2007;30(7):621–6.CrossRefPubMed Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Matsuoka H et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res. 2007;30(7):621–6.CrossRefPubMed
35.
Zurück zum Zitat Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007;333(6):321–6.CrossRefPubMed Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007;333(6):321–6.CrossRefPubMed
36.
Zurück zum Zitat Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–42.CrossRefPubMed Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234–42.CrossRefPubMed
37.
Zurück zum Zitat Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011;34(3):308–13.CrossRefPubMed Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011;34(3):308–13.CrossRefPubMed
38.
Zurück zum Zitat Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl. 2006;24(1):S95–9.CrossRefPubMed Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl. 2006;24(1):S95–9.CrossRefPubMed
39.
Zurück zum Zitat Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45(4):526–9.CrossRefPubMed Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45(4):526–9.CrossRefPubMed
40.
Zurück zum Zitat Matsuura K, Hagiwara N. The pleiotropic effects of ARB in vascular endothelial progenitor cells. Curr Vasc Pharmacol. 2011;9(2):153–7.CrossRefPubMed Matsuura K, Hagiwara N. The pleiotropic effects of ARB in vascular endothelial progenitor cells. Curr Vasc Pharmacol. 2011;9(2):153–7.CrossRefPubMed
41.
Zurück zum Zitat Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32(2):115–21.CrossRefPubMed Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32(2):115–21.CrossRefPubMed
Metadaten
Titel
Mechanism by which chronic kidney disease causes cardiovascular disease and the measures to manage this phenomenon
verfasst von
Eiji Kusano
Publikationsdatum
01.10.2011
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2011
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0461-x

Weitere Artikel der Ausgabe 5/2011

Clinical and Experimental Nephrology 5/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.